The Experts below are selected from a list of 56031 Experts worldwide ranked by ideXlab platform

H R O - One of the best experts on this subject based on the ideXlab platform.

  • three cases of pruritic urticarial papules and plaques of pregnancy puppp treated with Intramuscular Injection of autologous whole blood
    Journal of The European Academy of Dermatology and Venereology, 2015
    Co-Authors: I K Jeo, H R O
    Abstract:

    Background Pruritic urticarial papules and plaques of pregnancy (PUPPP), also known as polymorphic eruption of pregnancy, is a common and benign but exceedingly uncomfortable dermatosis of pregnancy. Investigation of new treatment options has been limited by patient concerns about the negative fetal effects of medication. Objective To assess the efficacy of Intramuscular Injection of autologous whole blood (AWB) for treatment of PUPPP. Methods This is a retrospective descriptive case series of three patients with PUPPP, all of whom were treated with Intramuscular Injection of AWB. Results All patients showed good responses to Intramuscular Injection of AWB, tolerated the treatment, and there were no adverse effects to the patients or their babies. Conclusion AWB may be an alternative treatment option for patients with PUPPP who are worried about the risk of medication use during pregnancy or breastfeeding. Whole blood collected from the patient's own body may be preferable to foreign medications. Future investigation into the exact mechanism with controlled clinical studies using a large number of patients will be necessary to provide supporting evidence for this potential treatment.

Michèle Cottier - One of the best experts on this subject based on the ideXlab platform.

  • Testicular biodistribution of silica-gold nanoparticles after Intramuscular Injection in mice
    Biomedical Microdevices, 2015
    Co-Authors: Lara Leclerc, Jean-philippe Klein, Valérie Forest, Delphine Boudard, Matteo Martini, Jérémie Pourchez, Marie-geneviève Blanchin, Michèle Cottier
    Abstract:

    With the continuing development of nanomaterials, the assessment of their potential impact on human health, and especially human reproductive toxicity, is a major issue. The testicular biodistribution of nanoparticles remains poorly studied. This study investigated whether gold-silica nanoparticles could be detected in mouse testes after Intramuscular Injection, with a particular focus on their ability to cross the blood–testis barrier. To that purpose, well-characterized 70-nm gold core–silica shell nanoparticles were used to ensure sensitive detection using high-resolution techniques. Testes were collected at different time points corresponding to spermatogenesis stages in mice. Transmission electron microscopy and confocal microscopy were used for nanoparticle detection, and nanoparticle quantification was performed by atomic emission spectroscopy. All these techniques showed that no particles were able to reach the testes. Results accorded with the normal histological appearance of testes even at 45 days post sacrifice. High-resolution techniques did not detect 70-nm silica-gold nanoparticles in mouse testes after Intramuscular Injection. These results are reassuring about the safety of nanoparticles with regard to male human reproduction, especially in the context of nanomedicine.

  • Testicular biodistribution of 450 nm fluorescent latex particles after Intramuscular Injection in mice.
    Biomedical Microdevices, 2013
    Co-Authors: Jean-philippe Klein, Valérie Forest, Delphine Boudard, Jérémie Pourchez, Josette Cadusseau, Sabine Palle, Michèle Cottier
    Abstract:

    The significant expansion in the use of nanoparticles and submicron particles during the last 20 years has led to increasing concern about their potential toxicity to humans and particularly their impact on male fertility. Currently, an insufficient number of studies have focused on the testicular biodistribution of particles. The aim of our study was to assess the distribution of 450 nm fluorescent particles in mouse testes after Intramuscular Injection. To this end, testes were removed from 5 groups of 3 mice each at 1 h (H1), 4 days (D4), 21 days (D21), 45 days (D45) and 90 days (D90) after the Injection of 7.28 × 10(9) particles in the tibialis anterior muscles of each mouse. We examined histological sections from these samples by epifluorescence microscopy and confocal microscopy and identified testicular biodistribution of a small number of particles in groups H1, D4, D21, D45 and D90. Using CD11b immunostaining, we showed that particles were not carried into the testis by macrophages. The intratesticular repartition of particles mainly followed testicular vascularization. Finally, we found some particles in seminiferous tubules but could not determine if the blood-testis barrier was crossed.

Christopher E Walsh - One of the best experts on this subject based on the ideXlab platform.

  • sustained and complete phenotype correction of hemophilia b mice following Intramuscular Injection of aav1 serotype vectors
    Molecular Therapy, 2001
    Co-Authors: Hengjun Chao, Paul E Monahan, Jude R Samulski, Christopher E Walsh
    Abstract:

    We previously reported that direct Intramuscular Injection of non-serotype-2 AAV vectors, especially AAV serotype 1 (AAV1), resulted in expression of supranormal levels of canine F9 in immunodeficient mice. Here we test the ability of the AAV1-F9 vector to deliver sustained expression and correction of factor IX (FIX) deficiency in genetically engineered hemophilic mice. Intramuscular Injection of AAV1-F9 resulted in 100–1000 times more canine F9 in plasma of recombinant AAV1-F9 mice compared with Injection of AAV2-F9. Assessment of clotting activity by activated partial thromboplastin time confirmed that circulating canine FIX was indeed functional. Moreover, phenotypic correction assayed by tail clip challenge resulted in survival of all AAV1-F9 treated animals, in contrast to naive mice and 50% of AAV2-treated hemophilia B mice, which failed to survive. Administration of cyclophosphamide (CTX) was required to suppress formation of anti-canine FIX antibodies for AAV2-treated animals, whereas it was dispensable for those treated with AAV1-F9. This difference in immunogenicity further emphasizes the usefulness of serotype-specific vectors. Finally, we report that correction of the hemophilia phenotype using AAV1-F9 was complete and persistent (over 8 months), a result that underscores the value of continued exploration of alternative AAV serotype vectors.

  • direct Intramuscular Injection with recombinant aav vectors results in sustained expression in a dog model of hemophilia
    Gene Therapy, 1998
    Co-Authors: Paul E Monahan, Richard J Samulski, J Tazelaar, Xiao Xiao, Timothy C Nichols, Dwight A Bellinger, Marjorie S Read, Christopher E Walsh
    Abstract:

    Direct Intramuscular Injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia

I K Jeo - One of the best experts on this subject based on the ideXlab platform.

  • three cases of pruritic urticarial papules and plaques of pregnancy puppp treated with Intramuscular Injection of autologous whole blood
    Journal of The European Academy of Dermatology and Venereology, 2015
    Co-Authors: I K Jeo, H R O
    Abstract:

    Background Pruritic urticarial papules and plaques of pregnancy (PUPPP), also known as polymorphic eruption of pregnancy, is a common and benign but exceedingly uncomfortable dermatosis of pregnancy. Investigation of new treatment options has been limited by patient concerns about the negative fetal effects of medication. Objective To assess the efficacy of Intramuscular Injection of autologous whole blood (AWB) for treatment of PUPPP. Methods This is a retrospective descriptive case series of three patients with PUPPP, all of whom were treated with Intramuscular Injection of AWB. Results All patients showed good responses to Intramuscular Injection of AWB, tolerated the treatment, and there were no adverse effects to the patients or their babies. Conclusion AWB may be an alternative treatment option for patients with PUPPP who are worried about the risk of medication use during pregnancy or breastfeeding. Whole blood collected from the patient's own body may be preferable to foreign medications. Future investigation into the exact mechanism with controlled clinical studies using a large number of patients will be necessary to provide supporting evidence for this potential treatment.

Jean-philippe Klein - One of the best experts on this subject based on the ideXlab platform.

  • Testicular biodistribution of silica-gold nanoparticles after Intramuscular Injection in mice
    Biomedical Microdevices, 2015
    Co-Authors: Lara Leclerc, Jean-philippe Klein, Valérie Forest, Delphine Boudard, Matteo Martini, Jérémie Pourchez, Marie-geneviève Blanchin, Michèle Cottier
    Abstract:

    With the continuing development of nanomaterials, the assessment of their potential impact on human health, and especially human reproductive toxicity, is a major issue. The testicular biodistribution of nanoparticles remains poorly studied. This study investigated whether gold-silica nanoparticles could be detected in mouse testes after Intramuscular Injection, with a particular focus on their ability to cross the blood–testis barrier. To that purpose, well-characterized 70-nm gold core–silica shell nanoparticles were used to ensure sensitive detection using high-resolution techniques. Testes were collected at different time points corresponding to spermatogenesis stages in mice. Transmission electron microscopy and confocal microscopy were used for nanoparticle detection, and nanoparticle quantification was performed by atomic emission spectroscopy. All these techniques showed that no particles were able to reach the testes. Results accorded with the normal histological appearance of testes even at 45 days post sacrifice. High-resolution techniques did not detect 70-nm silica-gold nanoparticles in mouse testes after Intramuscular Injection. These results are reassuring about the safety of nanoparticles with regard to male human reproduction, especially in the context of nanomedicine.

  • Testicular biodistribution of 450 nm fluorescent latex particles after Intramuscular Injection in mice.
    Biomedical Microdevices, 2013
    Co-Authors: Jean-philippe Klein, Valérie Forest, Delphine Boudard, Jérémie Pourchez, Josette Cadusseau, Sabine Palle, Michèle Cottier
    Abstract:

    The significant expansion in the use of nanoparticles and submicron particles during the last 20 years has led to increasing concern about their potential toxicity to humans and particularly their impact on male fertility. Currently, an insufficient number of studies have focused on the testicular biodistribution of particles. The aim of our study was to assess the distribution of 450 nm fluorescent particles in mouse testes after Intramuscular Injection. To this end, testes were removed from 5 groups of 3 mice each at 1 h (H1), 4 days (D4), 21 days (D21), 45 days (D45) and 90 days (D90) after the Injection of 7.28 × 10(9) particles in the tibialis anterior muscles of each mouse. We examined histological sections from these samples by epifluorescence microscopy and confocal microscopy and identified testicular biodistribution of a small number of particles in groups H1, D4, D21, D45 and D90. Using CD11b immunostaining, we showed that particles were not carried into the testis by macrophages. The intratesticular repartition of particles mainly followed testicular vascularization. Finally, we found some particles in seminiferous tubules but could not determine if the blood-testis barrier was crossed.